Status: Recruiting
Epco, Zanu, Ritux for R/R FL or MZL
The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research study are: * Epcoritamab (a type of antibody) * Zanubrutinib (a type of Bruton tyrosine kinase inhibitor) * Rituximab (a type of monoclonal antibody)
Participants needed: 45
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Reid Merryman, MDUpdated: Feb 19, 2026Locations: 3
Eligibility criteria
Histologically confirmed diagnosis of CD20+ FL (grade 1-3A) or CD20+ MZL (any su... [+26]
Patients who require systemic immunosuppressive therapy for an ongoing medical c... [+32]